Physician profile
Jonathan David Benson
NPI 1417913492
$1,082.92
in general payments reported to CMS, 2019-2025
15 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $26.86 · 2022: $41.34 · 2023: $78.49 · 2024: $81.75 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.14 | 2019-2025 | Rinvoq |
| Pfizer INC. | $128.83 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.87 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.28 | 2019-2025 | Xifaxan |
| Novo Nordisk INC | $43.43 | 2025 | Wegovy |
| Ardelyx, INC. | $38.89 | 2025 | Ibsrela |
| Ethicon US, LLC | $29.06 | 2025 | Vistaseal, Surgiflo Hemostatic Matrix, Stratafix |
| Genzyme Corporation | $24.04 | 2022 | |
| Romark Laboratories, Lc | $23.55 | 2019 | |
| Aimmune Therapeutics, INC. | $20.62 | 2025 | Zenpep |
| Medtronic, INC. | $20.05 | 2025 | Pillcam |
| Gilead Sciences, INC. | $19.50 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.98 | 2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $17.30 | 2022 | |
| Shionogi INC | $16.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.